Association of Cytomegalovirus Immunoglobulin G Antibodies with Prevalent and De Novo Hypertension in People With HIV.

IF 3.1 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2025-09-24 DOI:10.1097/QAD.0000000000004355

Kristiana A Nikolova, Dina L Møller, Josefine A Loft, Moises A Suarez-Zdunek, Nikolai Kirkby, Thomas Benfield, Raquel Martin-Iguacel, Andreas D Knudsen, Susanne D Nielsen

{"title":"Association of Cytomegalovirus Immunoglobulin G Antibodies with Prevalent and De Novo Hypertension in People With HIV.","authors":"Kristiana A Nikolova, Dina L Møller, Josefine A Loft, Moises A Suarez-Zdunek, Nikolai Kirkby, Thomas Benfield, Raquel Martin-Iguacel, Andreas D Knudsen, Susanne D Nielsen","doi":"10.1097/QAD.0000000000004355","DOIUrl":null,"url":null,"abstract":"Objective: People with HIV (PWH) have high burden of cardiovascular diseases, with cytomegalovirus (CMV) suggested to contribute to the CVD pathogenesis. However, research on CMV and hypertension in PWH is limited. We investigated whether CMV IgG seropositivity and concentrations are associated with prevalent and de novo hypertension in PWH.Design: Longitudinal study of PWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) study.Methods: Participants with available CMV IgG concentrations, blood pressure, and data on use of antihypertensives were included. Associations between CMV IgG seropositivity and high CMV IgG concentrations (>180 U/mL) with prevalent and de novo hypertension at two-year follow-up were analysed using logistic regression adjusted for age, sex, ethnic origin, body mass index, smoking, and CD4+ T-cell nadir.Results: We included 1,036 PWH, 95% were CMV IgG seropositive, and 41% had prevalent hypertension. Median CMV IgG concentration was higher among those with hypertension (159 U/mL, IQR 124-501) than those without (147 U/mL, IQR 114-455) (p = 0.001). The incidence rate of de novo hypertension was 8.3 cases per 100 person-years. CMV IgG seropositivity (adjusted odds ratio [aOR] 0.61 [95% confidence interval (CI): 0.32-1.16], p = 0.13) and high CMV IgG concentrations (aOR 1.09 [95% CI: 0.80-1.50], p = 0.58) were not associated with prevalent hypertension. Likewise, no associations were observed between CMV IgG seropositivity (aOR 1.75 [95% CI: 0.61-7.40], p = 0.36) or high CMV IgG concentrations (aOR 1.20 [95% CI: 0.74-1.93], p = 0.46) and de novo hypertension.Conclusions: We found no association between CMV IgG serostatus or concentrations and prevalent or de novo hypertension in PWH.","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004355","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: People with HIV (PWH) have high burden of cardiovascular diseases, with cytomegalovirus (CMV) suggested to contribute to the CVD pathogenesis. However, research on CMV and hypertension in PWH is limited. We investigated whether CMV IgG seropositivity and concentrations are associated with prevalent and de novo hypertension in PWH.

Design: Longitudinal study of PWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) study.

Methods: Participants with available CMV IgG concentrations, blood pressure, and data on use of antihypertensives were included. Associations between CMV IgG seropositivity and high CMV IgG concentrations (>180 U/mL) with prevalent and de novo hypertension at two-year follow-up were analysed using logistic regression adjusted for age, sex, ethnic origin, body mass index, smoking, and CD4+ T-cell nadir.

Results: We included 1,036 PWH, 95% were CMV IgG seropositive, and 41% had prevalent hypertension. Median CMV IgG concentration was higher among those with hypertension (159 U/mL, IQR 124-501) than those without (147 U/mL, IQR 114-455) (p = 0.001). The incidence rate of de novo hypertension was 8.3 cases per 100 person-years. CMV IgG seropositivity (adjusted odds ratio [aOR] 0.61 [95% confidence interval (CI): 0.32-1.16], p = 0.13) and high CMV IgG concentrations (aOR 1.09 [95% CI: 0.80-1.50], p = 0.58) were not associated with prevalent hypertension. Likewise, no associations were observed between CMV IgG seropositivity (aOR 1.75 [95% CI: 0.61-7.40], p = 0.36) or high CMV IgG concentrations (aOR 1.20 [95% CI: 0.74-1.93], p = 0.46) and de novo hypertension.

Conclusions: We found no association between CMV IgG serostatus or concentrations and prevalent or de novo hypertension in PWH.

查看原文本刊更多论文

巨细胞病毒免疫球蛋白G抗体与HIV感染者流行和新生高血压的关系

目的：HIV感染者（PWH）是心血管疾病的高负担人群，巨细胞病毒（CMV）可能与心血管疾病的发病有关。然而，关于巨细胞病毒与PWH患者高血压的研究还很有限。我们调查了巨细胞病毒IgG血清阳性和浓度是否与PWH患者的流行和新生高血压相关。设计：对哥本哈根HIV感染共病（COCOMO）研究中的PWH进行纵向研究。方法：纳入具有CMV IgG浓度、血压和抗高血压药物使用数据的参与者。在两年的随访中，CMV IgG血清阳性和高CMV IgG浓度（>180 U/mL）与流行和新发高血压之间的关系通过调整年龄、性别、种族、体重指数、吸烟和CD4+ t细胞最低水平的logistic回归分析。结果：我们纳入了1,036名PWH， 95% CMV IgG血清阳性，41%患有高血压。高血压组CMV IgG中位浓度（159 U/mL, IQR 124-501）高于无高血压组（147 U/mL, IQR 114-455）（p = 0.001）。新发高血压的发病率为8.3例/ 100人年。CMV IgG血清阳性（校正优势比[aOR] 0.61[95%可信区间（CI）： 0.32-1.16], p = 0.13）和高CMV IgG浓度（aOR 1.09 [95% CI: 0.80-1.50], p = 0.58）与高血压无相关性。同样，CMV IgG血清阳性（aOR为1.75 [95% CI: 0.61-7.40], p = 0.36）或CMV IgG高浓度（aOR为1.20 [95% CI: 0.74-1.93], p = 0.46）与新生高血压之间没有关联。结论：我们发现巨细胞病毒IgG血清状态或浓度与PWH患者的流行或新发高血压无关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.